Clinical trials: Gram-Positive Bacterial Infections
Pneumococcal Infections
Safety and Local Tolerability of Prevenar in Indian Children
This postmarketing surveillance study will evaluate the safety profile of Prevenar in Indian children. Prevenar is indicated for active immunization of infants and children from 6 weeks of age through 9 years of age against…
- Trial name
- NCT00488800
- Testing
- pneumococcal conjugate vaccine
- Volunteers
- 1,000 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Anthrax
Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers
This study will determine the safety and PK of a single IV dose of ETI-204 in subjects 18 to 65 years of age. Three cohorts will be studied with subjects receiving ETI-204.
- Trial name
- NCT01453907
- Testing
- ETI-204, "Anthim"
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Elusys Therapeutics
Tetanus, Poliomyelitis
Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™
The aim of this study is to assess antibody persistence in infants who received three doses of Infanrix hexa™ (DTPa-HBV-IPV/Hib) or Infanrix-IPV/Hib™ (DTPa-IPV/Hib) at 3, 5 and 11 months of age in study NCT00307034.
- Conditions
- Tetanus, Poliomyelitis, Haemophilus Influenzae Type b, Acellular Pertussis
- Trial name
- NCT01358825
- Testing
- Blood Sampling
- Where
- 4 sites in Norway, Sweden
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Lung Cancer
Charcoal in Lung Cancer Patients Undergoing TEMLA
This proof-of-concept study serves as the preliminary step to prove safety of oral activated charcoal (OAC) in patients with solid tumors before moving to a hematologic malignancy patient population.
- Trial name
- NCT04928950
- Testing
- Activated charcoal
- Sponsor
- Masonic Cancer Center, University of Minnesota
Tuberculosis, Multidrug-Resistant
High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis
The need for a standardized treatment protocol for multidrug resistant tuberculosis (MDR-TB) in resource-limited countries is being increasingly recognized.
- Trial name
- NCT00513396
- Testing
- Isoniazid
- Volunteers
- 134 people
- Sponsor
- GSVM Medical College
Tuberculosis
Development of a Clinical-epidemiological Score Predictive of Tuberculosis.
Despite being a curable and preventable disease, tuberculosis still represents a major global health problem. It is estimated that 10.8 million people contracted tuberculosis in 2023, with an incidence of 134 per 100,000…
- Trial name
- SCORE-TB (NCT07485868)
- Testing
- Development and validation of a clinical-epidemiological predictive score for the diagnosis of pulmonary tuberculosis
- Volunteers
- 686 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Clostridioides Difficile Infection
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
The purpose of this study is to evaluate the efficacy and safety of AZD5148 for prevention of recurrence of Clostridioides difficile infection in Individuals 18 years of age and above.
- Trial name
- PRISM (NCT07285213)
- Testing
- AZD5148
- Where
- 117 sites in United States, Australia and 12 more
- Volunteers
- 230 people
- Sponsor
- AstraZeneca
Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
The primary objective of the study is to determine whether dietary intervention to increase fiber and decrease fat reduces C. difficile infection recurrence in a cohort of oncology patients.
- Conditions
- Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute, Lymphoma, Clostridium Difficile Infection
- Trial name
- NCT04940468
- Testing
- Diet Intervention
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Colorado, Denver
Staphylococcus Aureus Bacteremia
Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia
The primary objective is to determine if early infectious disease (ID) consultation (defined as within 48 hours of a positive blood culture) will reduce mortality rates from Staphylococcus aureus bacteremia (SAB).
- Trial name
- NCT00622882
- Testing
- infectious disease specialist consultation
- Where
- Singapore
- Volunteers
- 200 people
- Sponsor
- National University Hospital, Singapore
Mycobacterium Ulcerans Disease, Buruli Ulcer
Timing of Surgical Intervention in Buruli Ulcer Patients Treated With Antibiotics
SUMMARY Rationale: Buruli ulcer, caused by Mycobacterium ulcerans, is an ulcerative disease endemic in West Africa. It often leads to functional limitations.
- Trial name
- Burulitime (NCT01432925)
- Testing
- surgical intervention on Buruli ulcer
- Where
- 2 sites in Benin
- Volunteers
- 119 people
- Sponsor
- University Medical Center Groningen
Complicated Staphylococcus Aureus (S. Aureus) Infections (CSAI)
Target Attainment of Continuous Infusion Flucloxacillin and Cefazolin Coupled With TDM vs. Standard of Care Treatment in Patients With Complicated S. Aureus Infection
This prospective randomized, controlled interventional pilot trial, aims to compare the achievement of the optimal target concentration with continuously administered flucloxacillin (FLU) or cefazolin (CZO) coupled with TDM and…
- Trial name
- TARGET III (NCT05655091)
- Testing
- FLU or CZO as continuous infusion, standard FLU or CZO intermittent bolus administration
- Where
- Switzerland
- Volunteers
- 36 people
- Sponsor
- University Hospital, Basel, Switzerland
Tuberculosis, Tuberculosis, Pulmonary
Point-of-care Triage Test for Active Tuberculosis
Background: Tuberculosis (TB) is a bacterial lung infection leaving 3.6 million people undiagnosed each year. Thirty percent of infected people do not receive treatment due to failure to receive diagnostic testing or being lost…
- Trial name
- TriageTB (NCT04232618)
- Testing
- Multi-biomarker point-of-care test
- Where
- South Africa
- Volunteers
- 900 people
- Sponsor
- University of Stellenbosch
Leprosy
Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2)
This study will evaluate a combination of bedaquiline and rifampicin as post exposure prophylaxis (PEP) for leprosy in Comoros. It will be a follow-up to the PEOPLE trial on PEP with rifampicin, which is ending in 2022.
- Trial name
- BE-PEOPLE P2 (NCT05406479)
- Testing
- BE-PEP (Bedaquiline), SDR-PEP, BE-PEP (Rifampicine)
- Where
- Comoros
- Volunteers
- 313 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Infections, Streptococcal
Immune Memory Evaluation in Children Following a Primary Vaccination With Pneumococcal Conjugate Vaccines.
To evaluate the immunological memory against pneumococcal vaccine serotypes in children primed with conjugate vaccines by administering a booster dose of plain polysaccharide vaccine.
- Trial name
- NCT00333450
- Testing
- Pneumococcal vaccine
- Where
- 30 sites in Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Lung Diseases, Tuberculosis
Effectiveness of Public Health Model of Latent Tuberculosis Infection Control for High-Risk Adolescents
This study will determine the differential cumulative mean number of isoniazid (INH) pills completed over 9 to 12 months for adolescents assigned to one of the following two groups: 1) peer adherence coaching, parent training…
- Trial name
- NCT00233168
- Testing
- Adherence Program, Life Skills and Self-Esteem Training Program (Attention Control Arm)
- Where
- United States
- Volunteers
- 263 people
- Sponsor
- San Diego State University
Pneumococcal Infections, Streptococcus Pneumoniae Infections
Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults
This study is designed to evaluate the safety, tolerability, and immunogenicity of an investigational pneumococcal vaccine in healthy adult volunteers.
- Conditions
- Pneumococcal Infections, Streptococcus Pneumoniae Infections, Pneumococcal Pneumonia
- Trial name
- NCT01444352
- Testing
- Pneumococcal vaccine Formulation 1, Pneumococcal vaccine Formulation 2, Pneumococcal vaccine Formulation 3
- Where
- Switzerland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Tetanus
Real-time Artificial Intelligent (AI)-Assisted Muscle Ultrasound for Monitoring Muscle Mass Reduction in ICU Patients
This study aims to investigate the feasibility of using a real-time artificial intelligent (AI)-assisted tool for Rectus Femoris cross sectional area measurement from muscle ultrasound to improve reliability, reduce inter- and…
- Trial name
- RAIMUS (NCT06034093)
- Testing
- Real-time AI-assisted muscle ultrasound
- Where
- Vietnam
- Volunteers
- 254 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Pneumococcal Infections, Pneumococcal Vaccines
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V114 in healthy infants. The primary hypotheses are that: 1) V114 is non-inferior to Prevnar 13™ for the 13 shared serotypes between V114…
- Trial name
- PNEU-PED (NCT03893448)
- Testing
- V114, Prevnar 13™, RotaTeq™
- Where
- 81 sites in United States, Puerto Rico and 2 more
- Volunteers
- 1,720 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Tuberculosis, Latent Tuberculosis
The Epidemiology of TST Change in Korea
TST will be analyzed in young general population in Korea. Young adults undertake TST as CDC recommendation. Participants with chest radiograph showing active TB lesion are excluded from this study.
- Trial name
- NCT01850043
- Where
- South Korea
- Volunteers
- 5,552 people, healthy volunteers welcome
- Sponsor
- Asan Medical Center
Mycobacterium Tuberculosis Infection
Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants
The trial is designed as a phase III, double-blind, multicenter, randomized, single administration, active-controlled, parallel-group design with two groups of newborn infants receiving either VPM1002 or BCG SII (1:1 allocation)…
- Trial name
- VPM1002 (NCT04351685)
- Testing
- VPM1002, BCG SII
- Where
- 12 sites in Gabon, Kenya and 3 more
- Volunteers
- 6,940 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.